SCHEDULE: Soleus Capital Discloses 5.1% Stake in Biodesix
Schedule 13G Filing
Soleus Capital Master Fund, L.P. and affiliated entities have reported beneficial ownership of 5.1% of Biodesix Inc. common stock.
Summary
- Soleus Capital Master Fund, L.P., along with related entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, have jointly filed a Schedule 13G.
- This filing indicates beneficial ownership of 525,241 shares of Biodesix Inc. common stock.
- This holding represents approximately 5.1% of the total outstanding common stock.
- The filing date is June 17, 2026, and the information is based on Biodesix Inc. having 10,355,809 shares outstanding as of May 20, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an investment fund and does not contain operational or financial performance information about the company.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Biodesix Inc.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors or other entities that acquire a significant stake in a company but do not intend to influence or control the issuer's management. This filing indicates a passive investment by Soleus Capital in Biodesix Inc.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding significant ownership stakes, which can inform investment decisions.
- Company Management: The disclosure indicates a substantial passive investment, which may be noted by the board and management.
Key Dates
| Date | Description |
|---|---|
| 2026-05-20 | Date as of which Biodesix, Inc. had 10,355,809 shares of common stock outstanding. |
| 2026-06-11 | Date of Prospectus filing by Biodesix, Inc. with the SEC. |
| 2026-06-17 | Date of Event Which Requires Filing of this Statement (Schedule 13G filing date). |
| 2026-06-18 | Date of signatures on the Schedule 13G filing and Joint Filing Agreement. |
Keywords
Biodesix Inc, Schedule 13G, Soleus Capital, Beneficial Ownership, Common Stock, SEC Filing, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.